- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01446055
Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia
Transplantation of Autologous BM-MNC Processed by ResQ Separator and Conventional Manual Method for Patients With Chronic Limb Ischemia: a Multi-center Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Using autologous bone marrow mononuclear cells (BM-MNC) to treat patients with chronic limb ischemia has been proved safe and effective. However, processing bone marrow by Ficoll density gradient centrifugation is not only time consuming but also expensive. Manually processing of bone marrow also results in large variation in therapeutic cell quantity and quality which directly lead deviation of safety and efficacy of the cell therapy. This study is aiming to compare an automated bone marrow processing system with a conventional manual method in term of safety and efficacy.
ResQ system developed by Thermogenesis in USA provides an automatic cell processing system for bone marrow. The system takes less than 30 minutes to concentrate the therapeutic mononuclear cells including stem cells in a closed system without adding any additive such as separation reagent (Ficoll). The system also be able to be operated at point of care.
The study is designed to prove no inferior of safety and efficacy of bone marrow cells processed by ResQ to those of cells using conventional manual method. The conventional manual method is involved Ficoll density gradient centrifugation and cell washing stems in an open system. Each of test arms (ResQ vs manual method) consists of 25 patients. The primary outcome is safety which is measured by cell treatment-related adverse events. The secondary endpoints include resting ankle-brachial pressure index (ABI)and toe brachial pressure index (TBI) , transcutaneous oxygen pressure (TcPO2), claudication distance, rest pain scale evaluation, collateral vessel scale, etc.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yongquan Gu, MD
- Phone Number: 13910002909
- Email: gu-yq@263.net
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Xuan Wu Hospital
-
Contact:
- Yongquan Gu, MD
- Phone Number: 13910002909
- Email: gu-yq@263.net
-
Principal Investigator:
- Yongquan Gu, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- fontaine's stage 2-4 or resting ABI <0.7
- age between 20 and 80 years old
- sign informed consent, voluntary subjects
- diagnosis of lower extremity arterial occlusive disease, or diabetic lower limb ischemia, or Buerger's disease
Exclusion Criteria:
- poorly controlled diabetes (HBA1c> 7.0%) and proliferative retinopathy (III-IV stage)
- malignancy history in the past five years or serum level of tumor markers elevated more than doubled
- severe heart, liver, kidney, respiratory failure or poor general condition can not tolerate BM-MNC transplantation
- serious infections (such as cellulitis, osteomyelitis, etc.)or gangrene that a major amputation cannot be avoided
- aortic or iliac or common femoral artery occlusion
- pregnant female, or reproductive age female who wants to give birth throughout the course of the study
- life expectancy less than a year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ResQ process group
Autologous BM-MNC is enriched with ResQ process(an automatic cell separator).
Then the cell product is transplanted into the ischemia limbs of a patient.
|
Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
|
Active Comparator: Ficoll-based conventional method
A conventional method based on Ficoll cell separation is used to process bone marrow.
|
Comparison of different cell processing methods
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cell treatment-related adverse event
Time Frame: 2-wk after bone marrow transplantation
|
|
2-wk after bone marrow transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ulcer size
Time Frame: Post bone marrow transplantation: 1, 3, 6, 12 months
|
Measuring ulcer area (cm2) and depth (mm)of limb : For each ulcer , photographically record the area and depth with a ruler in order to calculate the ulcer area in square millimeters. |
Post bone marrow transplantation: 1, 3, 6, 12 months
|
rest pain score.
Time Frame: Post bone marrow transplantation: 1,3, 6, 12 months
|
Scoring the rest pain based on the degree of pain as following five scales): 0 level-0 point: no pain;
Before transplantation: points; after transplantation: points. |
Post bone marrow transplantation: 1,3, 6, 12 months
|
cold sensation score
Time Frame: Post bone marrow transplantation:,1,3, 6, 12 months
|
based on a sense of cold as following five scales: 0 level-0 point: no cold sensation;
|
Post bone marrow transplantation:,1,3, 6, 12 months
|
claudication distance (m)
Time Frame: Post bone marrow transplantation:1, 3, 6, 12 months
|
Measurement of claudication distance (m): For patients with intermittent claudication, treadmill exercise test (no tilt, speed 3km/hr) is employed to measure claudication distance.
|
Post bone marrow transplantation:1, 3, 6, 12 months
|
Resting ABI
Time Frame: Post bone marrow transplantation: 1,3, 6, 12 months
|
Measurement of ABI(ankle brachial index, ABI): Measure arterial pressure with a laser Doppler, and then calculate the ankle-brachial index, that is a ratio of ankle arterial blood pressure to brachial arterial blood pressure at rest. |
Post bone marrow transplantation: 1,3, 6, 12 months
|
Resting TcPO2 (mmHg)
Time Frame: Post bone marrow transplantation:1, 3, 6, 12 months
|
Transcutaneous oxygen pressure(TcPO2) should be measured at the same site in the ischemic limb at rest.
|
Post bone marrow transplantation:1, 3, 6, 12 months
|
Collateral vessel score
Time Frame: Post bone marrow transplantation: 1,3, 6, 12 months
|
Collateral vessel score: Using DSA(Digital subtraction angiography)or CTA(computed tomographic angiography) to score the collateral vessel formation. A mean score is obtained for each ischemic limb by 3 independent interventionists based on the following 4 level score: 0 (no new collateral vessels)
|
Post bone marrow transplantation: 1,3, 6, 12 months
|
Amputation rate
Time Frame: Post bone marrow transplantation:1, 3, 6, 12 months
|
Amputation rate and level is recorded.
|
Post bone marrow transplantation:1, 3, 6, 12 months
|
Skin microcirculation measurement
Time Frame: 1,3,6,12 months post transplantation
|
using PeriMed "laser-Doppler flowmetry" measure the skin microcirculation on the same site in the ischemic limb at rest.
|
1,3,6,12 months post transplantation
|
Resting TBI
Time Frame: Post bone marrow transplantation: 1,3, 6, 12 months
|
Measurement of TBI(Toe Brachial Index): Measure arterial pressure with a laser Doppler, and then calculate Toe Brachial Index, that is a ratio of toe arterial blood pressure to brachial arterial blood pressure. |
Post bone marrow transplantation: 1,3, 6, 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yong-Quan Gu, Dr., Xuanwu Hospital, Beijing
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TGResQ082011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on ResQ processed bone marrow sample
-
Central Hospital, Nancy, FranceUnknownAllogeneic Stem Cell Transplantation | Relapse Leukemia | Immune Evasion, Tumor
-
Centre Hospitalier Universitaire, AmiensCentre Henri Becquerel; University Hospital, Caen; University Hospital, Lille; Centre...WithdrawnWaldenstrom Macroglobulinemia | Waldenstrom's DiseaseFrance
-
BioCardia, Inc.Not yet recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingSolid Tumor, Adult | Solid Tumor, Childhood | Hematologic CancerFrance
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingMyelodysplastic Syndromes | Purpura, Thrombocytopenic | ThrombocytopeniaFrance
-
Central Hospital, Nancy, FranceRecruitingAllogeneic Hematopoietic Stem Cell TransplantationFrance
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Myeloid Leukemia | Genetic Predisposition to Disease
-
Nantes University HospitalCompletedPened Chest Surgery for Programmes Coronary BypassFrance
-
Children's Oncology GroupNational Cancer Institute (NCI); Incuron LLCRecruitingRefractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditionsUnited States
-
Sanford HealthActive, not recruiting